Sanford Deuel County Medical Center

CLIA Laboratory Citation Details

3
Total Citations
10
Total Deficiencyies
9
Unique D-Tags
CMS Certification Number 43D0407349
Address 701 3rd Avenue South, Clear Lake, SD, 57226
City Clear Lake
State SD
Zip Code57226
Phone(605) 874-2141

Citation History (3 surveys)

Survey - May 17, 2022

Survey Type: Standard

Survey Event ID: 1YEN11

Deficiency Tags: D6028 D5481 D0000

Summary:

Summary Statement of Deficiencies D0000 A recertification survey for compliance with 42 CFR Part 493, Requirements for Laboratories, was conducted on 5/17/22. The Sanford Deuel County Medical Center laboratory was found not in compliance with the following requirements: D5481 and D6028. D5481 CONTROL PROCEDURES CFR(s): 493.1256(f)(g) (f) Results of control materials must meet the laboratory's and, as applicable, the manufacturer's test system criteria for acceptability before reporting patient test results. (g) The laboratory must document all control procedures performed. This STANDARD is not met as evidenced by: Based on record review and interview, the laboratory failed to ensure quality control (QC) results met established acceptability criteria before reporting patient test results for 11 of 30 days (4/14/22 through 4/25/22) reviewed. Findings include: 1. Review on 5/17/22 of the laboratory's daily QC records for the month of April 2022, revealed: *The laboratory used the Abbott Cell-Dyn Emerald analyzer for the testing of patient hematology specimens. *Three levels of control (low, normal, and high) had been run each day of patient testing to ensure the accuracy of patient specimen results prior to reporting. *Hematology control results had been printed after each run. QC values outside the acceptable were printed in bold with a comment code ( L-below the acceptable range and H-above the acceptable range). *Abbott Cell-Dyn Systems Hematology control Lot number 2038, expiring 5/27/22, had been the controls in use. *The laboratory had accepted the manufacturer's stated package insert ranges for acceptability. *The Abbott Cell Dyn Hematology Control manufacturer's package insert acceptable ranges had been: -Low control red blood cell (RBC) count 2.0-2.8 million per cubic milliliter (/cml). -Normal control white blood cell (WBC) count 7.5- 9.5 thousand/cml. -Normal control RBC count 4.05-4.55 million/cml. -High control WBC count 15.5-20.5 thousand/cml. -High control RBC count 4.98-5.58 million/cml. Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 4 -- *There had been 12 consecutive days when QC was out of acceptable range. *On 4/14 /22 the control reports revealed: -The normal control had been analyzed 4 times. -- RBC results had been 4.83, 4.77, and 4.74 million/cml. -The high control had been analyzed 3 times. --RBC results had been 4.88, 4.89, and 4.89 million/cml. -There had been no

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access

Survey - September 25, 2019

Survey Type: Standard

Survey Event ID: 4BFR11

Deficiency Tags: D0000 D5775 D2015 D5221 D3031

Summary:

Summary Statement of Deficiencies D0000 A recertification survey for compliance with 42 CFR Part 493, Requirements for Laboratories, was conducted on 9/25/19. The Sanford Deuel County Medical Center laboratory was found not in compliance with the following requirements: D2015, D3031, D5221, and D5775. D2015 TESTING OF PROFICIENCY TESTING SAMPLES CFR(s): 493.801(b)(5)(6) (5) The laboratory must document the handling, preparation, processing, examination, and each step in the testing and reporting of results for all proficiency testing samples. The laboratory must maintain a copy of all records, including a copy of the proficiency testing program report forms used by the laboratory to record proficiency testing results including the attestation statement provided by the PT program, signed by the analyst and the laboratory director, documenting that proficiency testing samples were tested in the same manner as patient specimens, for a minimum of two years from the date of the proficiency testing event. (6) PT is required for only the test system, assay, or examination used as the primary method for patient testing during the PT event. This STANDARD is not met as evidenced by: Based on review of American Proficiency Institute (API) proficiency testing (PT) records and interview with the laboratory supervisor, the laboratory failed to ensure each step in the PT process had been documented for 19 of 19 API PT events reviewed (2018 first, second, and third chemistry core, hematology/coagulation, and microbiology events; 2019 first, second, and third chemistry core events; 2019 first and second hematology/coagulation,microbiology and immunohematology events; and 2019 first chemistry miscellaneous event). Findings include: 1. Review of 2018 and to date 2019 API PT records revealed laboratory staff had failed to complete the proficiency testing worksheet for the reveiwed PT testing events. That worksheet documented the receipt, acceptability, and handling of PT samples. Interview on 9/25 Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 3 -- /19 at 9:45 a.m. with the laboratory supervisor revealed she had been aware the PT worksheets had been used in the past. She had quit using them as she thought they were no longer required. She agreed the worksheets should have been completed. D3031 RETENTION REQUIREMENTS CFR(s): 493.1105(a)(3) Analytic systems records. Retain quality control and patient test records (including instrument printouts, if applicable) and records documenting all analytic systems activities specified in 493.1252 through 493.1289 for at least 2 years. This STANDARD is not met as evidenced by: Based on record review, observation, and interview with laboratory supervisor, the laboratory failed to retain the results of the daily background checks from the Abbott Emerald hematology analyzer for approximately 8 of 15 months (July 2018 to February 2019) to ensure critical operating characteristics that affected the stability and calibration of the analyzer met specific criteria defined by the manufacturer. Findings include: 1. Observation and demonstration on 9/25/19 at 12:05 p.m. of the Abbott Emerald hematology analyzer's electronic files revealed the oldest background count retained was dated 3/1/19. Interview with the laboratory supervisor on 9/25/19 at 12:05 p.m. revealed: *The analyzer had been placed into service July 2018. *She had thought all background check results had been stored electronically. *Background checks had been performed as part of daily start-up procedures with acceptable results. *No other log such as paper or a spreadsheet had been kept of the results. D5221 EVALUATION OF PROFICIENCY TESTING PERFORMANCE CFR(s): 493.1236(d) All proficiency testing evaluation and verification activities must be documented. This STANDARD is not met as evidenced by: Based on review of American Proficiency Institute (API) proficiency testing (PT) events, review of performance improvement reports and interview with the laboratory supervisor, the laboratory failed to ensure PT results had been reviewed, evaluated, and those activities documented for 6 of 18 PT events reviewed (2018 first chemistry core, 2018 first and second hematology/coagulation, 2018 second microbiology, 2019 first hematology/coagulation, and 2019 first chemistry miscellaneous events). Findings include: 1. Review of the 2018 API PT events revealed the following unacceptable or ungraded results: *Chemistry core first event: -Total cholesterol, sample CH-02, ungraded. -LDL (low density lipoprotein) calculated, sample CH-02, ungraded. *Hematology/coagulation first event: blood cell identification, sample BCI- 01, ungraded. *Hematology/coagulation second event: urine sediment, sample US-03, unacceptable. *Microbiology second event: potassium hydroxide (KOH) preparation, sample KOH-03, unacceptable. Review of the 2019 API PT events revealed the following ungraded results: *Hematology first event: -Blood cell identification (educational), samples E01-E05, ungraded. -Platelet count, sample HEM-02, ungraded. -Urine sediment, sample US-02, ungraded. -Vaginal wet preparation/KOH, VKP-01, ungraded. *Chemistry miscellaneous first event: UDS (urine drug screen) opiates, sample UDS-02, ungraded. Review of the laboratory's PT reports revealed there had been no investigation on unacceptable or ungraded results for the above listed samples. Review of the laboratory's 2018 Performance Improvement Summary -- 2 of 3 -- Form signed by the laboratory supervisor on 1/22/19 revealed: *"Reviewed 2018 Proficiency Testing: -Heme 1st event: 80% RBC, 80% Granulocytes, 80% Lymphocytes- reviewed -Heme 2nd event: 80% Blood Cell ID, 80% Hematocrit, 0% RBC- reviewed, new analyzer implemented -Action Taken: N/A Print out all reports needed -Re-evaluation procedure (when and how this activity will be reassessed): review annually" Interview on 9/25/19 at 9:45 a.m. with the lab supervisor revealed: *She thought all unacceptable and ungraded samples had been reviewed. *She confirmed there was no documentation the above samples had been reviewed. D5775 COMPARISON OF TEST RESULTS CFR(s): 493.1281(a)(c) (a) If a laboratory performs the same test using different methodologies or instruments, or performs the same test at multiple testing sites, the laboratory must have a system that twice a year evaluates and defines the relationship between test results using the different methodologies, instruments, or testing sites. (c) The laboratory must document all test result comparison activities. This STANDARD is not met as evidenced by: Based on review of the quality assessment (QA) activities, annual test volume form, and interview with the laboratory supervisor, the laboratory failed to establish criteria for acceptable differences between one of one test performed by multiple methodologies (manual white blood cell differential versus automated). The two methods had not been compared twice a year in 2018 to determine if their differences had been acceptable. Findings include: 1. Review of the laboratory's 2018 QA activities revealed there had been no comparison testing for white blood cell differential manual versus automated. Review of the annual test volume form revealed thirty-three manual differential patient tests had been performed in 2018 without the difference of the two test methods being evaluated for acceptability. Interview on 9/25 /19 at 11:05 a.m. with the laboratory supervisor revealed the laboratory had not documented the twice a year comparisons between manual and automated differentials. She stated, "It was supposed to be done in December." She was not aware it needed to be done twice a year. -- 3 of 3 --

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access

Survey - October 31, 2018

Survey Type: Special

Survey Event ID: ZWYM11

Deficiency Tags: D2130 D2016

Summary:

Summary Statement of Deficiencies D2016 SUCCESSFUL PARTICIPATION CFR(s): 493.803(a)(b)(c) (a) Each laboratory performing nonwaived testing must successfully participate in a proficiency testing program approved by CMS, if applicable, as described in subpart I of this part for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA. (b) Except as specified in paragraph (c) of this section, if a laboratory fails to participate successfully in proficiency testing for a given specialty, subspecialty, analyte or test, as defined in this section, or fails to take remedial action when an individual fails gynecologic cytology, CMS imposes sanctions, as specified in subpart R of this part. (c) If a laboratory fails to perform successfully in a CMS- approved proficiency testing program, for the initial unsuccessful performance, CMS may direct the laboratory to undertake training of its personnel or to obtain technical assistance, or both, rather than imposing alternative or principle sanctions except when one or more of the following conditions exists: (1) There is immediate jeopardy to patient health and safety. (2) The laboratory fails to provide CMS or a CMS agent with satisfactory evidence that it has taken steps to correct the problem identified by the unsuccessful proficiency testing performance. (3) The laboratory has a poor compliance history. This CONDITION is not met as evidenced by: Based on proficiency testing (PT) record review and interview with the laboratory supervisor, the laboratory failed to achieve successful performance for the test method erythrocyte count. Unsatisfactory results had been received in two of three PT events (Hematology/Coagulation 2017 3rd and 2018 2nd events) resulting in unsatisfactory PT performance. Refer to D2130. D2130 HEMATOLOGY CFR(s): 493.851(f) Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 2 -- Failure to achieve satisfactory performance for the same analyte in two consecutive events or two out of three consecutive testing events is unsuccessful performance. This STANDARD is not met as evidenced by: Based on review of CASPER Reports and interview with the laboratory supervisor, the laboratory failed to achieve satisfactory proficiency testing (PT) performance for the erythrocyte count test method in two out of three events (Hematology/Coagulation 2017 3rd and 2018 2nd events) resulting in unsuccessful performance. Findings include: 1. Review of the laboratory's CASPER Reports 153D and 155D revealed the American Proficiency Institute PT scores for the erythrocyte count (RBC) test method were less than the 80% required to pass the RBC test per CLIA requirements found at CFR 493.861(a): a. 2017 Hematology/Coagulation 3rd event RBC score = 40% (HSY- 11, 12, and 14 were graded as unacceptable). b. 2018 Hematology/Coagulation 2nd event RBC score = 0% (HSY-06, 07, 08, 09, and 10 were graded as unacceptable). 2. Interview with the laboratory supervisor on 8/20/18 confirmed the failure. She stated they were aware of the issue. She stated they had been having issues with the Abbott Emerald hematology analyzer and service had been contacted. The Hematology /Coagulation PT 2017 3rd and 2018 2nd events had been performed and reported on the older Abbot Emerald hematology analyzer. She stated they were in the process of validating a new replacement Abbott Emerald hematology analyzer. The new analyzer was put into use 7/17/18. -- 2 of 2 --

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access